This phase 3 trial tests whether adding eftilagimod alfa to standard immunotherapy (pembrolizumab) and chemotherapy helps people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 756 adults who have not had prior treatment for their adv…
Phase: PHASE3 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC